BMIQ1
MCID: BDY007
MIFTS: 40

Body Mass Index Quantitative Trait Locus 1 (BMIQ1)

Categories: Bone diseases, Genetic diseases, Mental diseases, Metabolic diseases

Aliases & Classifications for Body Mass Index Quantitative Trait Locus 1

MalaCards integrated aliases for Body Mass Index Quantitative Trait Locus 1:

Name: Body Mass Index Quantitative Trait Locus 1 57 13
Body Mass Index 57 17
Bmi 57 48
Body Mass Index; Bmi 57
Bmiq1 57

Classifications:



External Ids:

OMIM® 57 606641

Summaries for Body Mass Index Quantitative Trait Locus 1

OMIM® : 57 Body mass index (BMI), which reflects the amount of fat, lean mass, and body build, is a heterogeneous trait influenced by both genetic and environmental factors. Several studies have estimated the heritability of body mass index to be 40 to 55% (Bouchard et al., 1998; Rice et al., 1999). For discussion of genetic heterogeneity of BMI quantitative trait loci and their known or possible associations with variation in specific genes, see MAPPING and MOLECULAR GENETICS sections. (606641) (Updated 20-May-2021)

MalaCards based summary : Body Mass Index Quantitative Trait Locus 1, also known as body mass index, is related to body mass index quantitative trait locus 20 and body mass index quantitative trait locus 3. An important gene associated with Body Mass Index Quantitative Trait Locus 1 is BMIQ1 (Body Mass Index QTL 1). The drugs Benzocaine and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include breast, heart and liver.

Related Diseases for Body Mass Index Quantitative Trait Locus 1

Diseases in the Body Mass Index Quantitative Trait Locus 11 family:

Body Mass Index Quantitative Trait Locus 9 Body Mass Index Quantitative Trait Locus 8
Body Mass Index Quantitative Trait Locus 1 Body Mass Index Quantitative Trait Locus 2
Body Mass Index Quantitative Trait Locus 3 Body Mass Index Quantitative Trait Locus 4
Body Mass Index Quantitative Trait Locus 10 Body Mass Index Quantitative Trait Locus 7
Body Mass Index Quantitative Trait Locus 5 Body Mass Index Quantitative Trait Locus 6
Body Mass Index Quantitative Trait Locus 12 Body Mass Index Quantitative Trait Locus 13
Body Mass Index Quantitative Trait Locus 14 Body Mass Index Quantitative Trait Locus 15
Body Mass Index Quantitative Trait Locus 18 Body Mass Index Quantitative Trait Locus 19
Body Mass Index Quantitative Trait Locus 20

Diseases related to Body Mass Index Quantitative Trait Locus 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1217)
# Related Disease Score Top Affiliating Genes
1 body mass index quantitative trait locus 20 11.5
2 body mass index quantitative trait locus 3 11.5
3 body mass index quantitative trait locus 2 11.5
4 body mass index quantitative trait locus 5 11.5
5 body mass index quantitative trait locus 6 11.5
6 body mass index quantitative trait locus 13 11.5
7 body mass index quantitative trait locus 15 11.5
8 esophageal cancer 11.4
9 chromosome 16p11.2 deletion syndrome, 220-kb 11.3
10 siddiqi syndrome 11.3
11 mental retardation, x-linked 12 11.1
12 hypercholesterolemia, familial, 3 11.1
13 morbid obesity and spermatogenic failure 10.9
14 congestive heart failure 10.9
15 atrial fibrillation 10.8
16 liver disease 10.8
17 chronic kidney disease 10.8
18 arteries, anomalies of 10.8
19 lipoprotein quantitative trait locus 10.8
20 kidney disease 10.8
21 pulmonary disease, chronic obstructive 10.8
22 rheumatoid arthritis 10.8
23 hypercholesterolemia, familial, 1 10.7
24 end stage renal disease 10.7
25 myocardial infarction 10.7
26 rectum cancer 10.7
27 eclampsia 10.7
28 pustulosis of palm and sole 10.7
29 psoriasis 10.7
30 proteinuria, chronic benign 10.7
31 atherosclerosis susceptibility 10.7
32 dementia 10.7
33 ischemia 10.7
34 pancreatic cancer 10.7
35 stroke, ischemic 10.7
36 squamous cell carcinoma 10.6
37 adenocarcinoma 10.6
38 acute myocardial infarction 10.6
39 type 1 diabetes mellitus 10.6
40 thrombophilia due to thrombin defect 10.6
41 multiple sclerosis 10.6
42 hyperuricemia 10.6
43 ige responsiveness, atopic 10.6
44 hypothyroidism 10.6
45 pulmonary embolism 10.6
46 small cell cancer of the lung 10.6
47 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.6
48 hyperandrogenism 10.6
49 liver cirrhosis 10.6
50 crohn's disease 10.6

Graphical network of the top 20 diseases related to Body Mass Index Quantitative Trait Locus 1:



Diseases related to Body Mass Index Quantitative Trait Locus 1

Symptoms & Phenotypes for Body Mass Index Quantitative Trait Locus 1

Clinical features from OMIM®:

606641 (Updated 20-May-2021)

Drugs & Therapeutics for Body Mass Index Quantitative Trait Locus 1

Drugs for Body Mass Index Quantitative Trait Locus 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 283)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
2
tannic acid Approved Phase 4 1401-55-4
3
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
4
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
5
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
6
Ticagrelor Approved Phase 4 274693-27-5 9871419
7
Zinc Approved, Investigational Phase 4 7440-66-6 32051
8
Insulin detemir Approved Phase 4 169148-63-4 5311023
9
Pancrelipase Approved, Investigational Phase 4 53608-75-6
10
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
11
Sulbactam Approved Phase 4 68373-14-8
12
Sultamicillin Approved, Investigational Phase 4 76497-13-7
13
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
14
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
15
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
16
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
17
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
18
Simvastatin Approved Phase 4 79902-63-9 54454
19 calcium heparin Phase 4
20 Androgens Phase 4
21 Anti-Bacterial Agents Phase 4
22 Antibiotics, Antitubercular Phase 4
23 Contraceptive Agents Phase 4
24 Isophane Insulin, Human Phase 4
25 Isophane insulin, beef Phase 4
26 Insulin, Isophane Phase 4
27 pancreatin Phase 4
28 beta-Lactamase Inhibitors Phase 4
29 Reverse Transcriptase Inhibitors Phase 4
30 Raltegravir Potassium Phase 4
31 Anti-Retroviral Agents Phase 4
32 Anti-HIV Agents Phase 4
33 HIV Integrase Inhibitors Phase 4
34 HIV Protease Inhibitors Phase 4
35 Integrase Inhibitors Phase 4
36
protease inhibitors Phase 4
37 Contraceptives, Postcoital Phase 4
38 Contraceptives, Oral Phase 4
39 Ulipristal acetate Phase 4 126784-99-4
40 Chaste Tree Phase 4
41 Protective Agents Phase 4
42 Antioxidants Phase 4
43 Anesthetics Phase 4
44 Hormones Phase 4
45 Calcium, Dietary Phase 4
46 Neurotransmitter Agents Phase 4
47 Antihypertensive Agents Phase 4
48 Hypnotics and Sedatives Phase 4
49 Anesthetics, General Phase 4
50 Anesthetics, Intravenous Phase 4

Interventional clinical trials:

(show top 50) (show all 301)
# Name Status NCT ID Phase Drugs
1 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
2 PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor Unknown status NCT02698618 Phase 4 Randomization
3 Correlation of Postoperative VAS Values and Body Mass Index in Patients Undergoing Abdominal Surgery: A Clinical Trial Unknown status NCT02017314 Phase 4 Morphine
4 Analysis of Body Mass Index in Central Precocious Puberty(CPP) Patients Treated With Leuprolide Acetate Unknown status NCT02974270 Phase 4 Leuprolide
5 The Effect of Body Mass Index, Intra-abdominal Pressure, Abdominal Girth and Waist Circumference on Sensory Block Level After Single-shot Spinal Anesthesia for Cesarean Section Unknown status NCT03164096 Phase 4 Bupivacaine Hydrochloride
6 A Pilot Phase IV Study to Evaluate Variation in Bone Mineral Density, Lean and Fat Body Mass Index Measured by Dual-energy X-ray Absorptiometry in Patients With Prostate Cancer Without Bone Metastasis Treated With Degarelix Unknown status NCT03202381 Phase 4 Degarelix
7 A Cluster Randomized Trial of the Implementation of the NHLBI Expert Panel Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents Completed NCT01893593 Phase 4
8 NPH and Regular Insulin in the Treatment of Inpatient Hyperglycemia: Comparison of 3 Basal-bolus Regimens Completed NCT02758522 Phase 4 Once-daily Insulin;Twice-daily Insulin;Triple-daily Insulin
9 A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin (Levemir DIET) Completed NCT01232491 Phase 4 Insulin detemir
10 Double-Blind, Multicenter, Randomized, Placebo-Controlled, Parallel-Group Study to Investigate the Effect of Creon 25000 Minimicrospheres on Body Mass Index (BMI) in Patients After Gastrectomy Completed NCT00160186 Phase 4 Pancreatin;Placebo
11 Phase IV Study of Determining the Efficacy of Ampicillin/Sulbactam Combination as Antibiotic Prophylaxis During Breast Cancer Surgery in Patients With a Body Mass Index (BMI) Over 25. Completed NCT00356148 Phase 4 Ampicillin/Sulbactam
12 Effect on Liver Fat, Adipose Tissue and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Once Daily Raltegravir in HIV+ Patients With Body Mass Index Over 25 kg/m2 and With at Least One Metabolic Syndrome Component Completed NCT03374358 Phase 4 Raltegravir
13 Pharmacokinetics of Levonorgestrel and Ulipristal Acetate Emergency Contraception in Women With Normal and Obese Body Mass Index Completed NCT02689804 Phase 4 LNG-EC;UPA-EC
14 A Clinical Study of the Effects of Cyclodynon® Compared With a Control Group on Reducing the Cumulative Risk of Breast Cancer Development in a Female Population Aged 40-52 Years With Mastodynia and BI-RADS Category 3 Recruiting NCT04498013 Phase 4 Cyclodynon
15 Impact of Roux-en-Y Gastric Bypass (RYGB) Bariatric Surgery on System Pharmacology: Single-dose Cross-over Pharmacokinetic Study of Simvastatin and Carvedilol. Enrolling by invitation NCT04049786 Phase 4 Carvedilol 25mg;Metoprolol 100 mg;Simvastatin 40mg;Midazolam 2 mg
16 A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years Terminated NCT03338296 Phase 4 lorcaserin hydrochloride XR;Placebo
17 Simultaneous Study of Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as Well as Life Style Intervention Strategies Unknown status NCT00847444 Phase 3 Drug-based intervention
18 Treating Childhood Obesity With Family Lifestyle Change Completed NCT00528164 Phase 2, Phase 3
19 Portion Control for the Treatment of Obesity in the Primary Care Setting Completed NCT01451554 Phase 2, Phase 3
20 Preventing Excessive Weight Gain by Reducing Carbonated Beverage and Sugar Consumption and Increasing Physical Activity Among Public School Adolescents From the Metropolitan Area of Rio de Janeiro Completed NCT01046474 Phase 3
21 Phase 3: Effect of Diet, Physical Activity and Insulin Sensitizer Metformin on Obesity and Associated Risks in Children and Adolescents. Completed NCT01677923 Phase 3 Metformin
22 A Multinational, Randomised, Open-labelled, Parallel Group Four Months Comparison of Twice Daily Biphasic Human Insulin 30 and Thrice Daily Biphasic Insulin Aspart 50 and 70 in Subjects With Type 1 or Type 2 Diabetes Completed NCT01520818 Phase 3 biphasic insulin aspart 50;biphasic insulin aspart 70;biphasic human insulin 30
23 Effects of Zinc Supplementation on Weight, Body Mass Index (BMI), Waist Circumference, Fat Mass and Lean Mass, Apelin and Inflammatory Markers in Obese Individuals Completed NCT02516475 Phase 2, Phase 3
24 High Protein Diet , Adiponectin and Inflammatory Factors Completed NCT01886495 Phase 3
25 Effect of High Protein Diet on Cardiovascular Diseases Risk Factors Among Overweight and Obese Children Completed NCT01886482 Phase 3
26 High Protein Diet , CRP and CVD Risk Factors Completed NCT01763528 Phase 3
27 Could Transvaginal Ultrasonography Guided Embryo Transfer Improves Pregnancy Outcome in Obese Patients Undergoing Intracytoplasmic Sperm Inoculation? Randomized Controlled Study Completed NCT03473028 Phase 2, Phase 3
28 Effect of Mindful Eating on Body Mass Index and Cardiovascular Risk Markers in Obese Adolescents: A Pilot Randomized Clinical Trial Completed NCT01764113 Phase 3
29 Select A Multi-centre Randomised Prospective Open-label Study to Investigate the Efficacy & Safety of a Standardised Correction Dosage Regimen of i.v. Ferric Carboxymaltose Versus Iron Sucrose for Treatment of Iron Deficiency Anaemia in Patients With Inflammatory Bowel Disease Completed NCT00810030 Phase 3 Ferric carboxymaltose;Iron Sucrose
30 An Investigative, Prospective, Non-randomized, Multi-center Study to Assess the Safety and Effectiveness of a Novel Gastric Restrictive Device, Call the ReShape Vest™, in People Who Are Obese. Recruiting NCT03918564 Phase 2, Phase 3
31 An Endometrial Cancer Chemoprevention Study of Metformin Versus No Treatment in Women With a Body Mass Index (BMI) >/= 30 kg.m2 and Hyperinsulinemia Active, not recruiting NCT01697566 Phase 3 Metformin
32 Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma Active, not recruiting NCT02076009 Phase 3 Daratumumab;Lenalidomide;Dexamethasone
33 Guys/Girls Opt for Activities for Life Trial Suspended NCT04213014 Phase 3
34 Myo-inositol Versus Metformin Administration in Post-menopausal Women With Metabolic Syndrome Unknown status NCT01046500 Phase 2 Metformin
35 Effectiveness of an Intervention by a Health Education Workshop Compared With the Usual Advice to Reduce the Incidence of Falls in Independent 65 Years and Older Not Institutionalized. Primary Prevention.CHANGING TO NEVER FALL. CTNF Unknown status NCT02645006 Phase 2
36 Efficacy and Safety of Dexamethasone Prevention for Patients of Ovarian Hyperstimulation Syndrome -- A Prospective, Randomized, Controlled Clinical Trial Unknown status NCT02846493 Phase 2 bromocriptine;dexamethasone
37 A Randomized, Open Label, Two-part, Three-period, Cross Over Study to Investigate the Effects of Carbohydrate in Diet and to Evaluate Supplements on the Gastrointestinal Tolerability of LIK066 in Overweight or Obese Subjects Completed NCT03198767 Phase 2 LIK066
38 Influence of Long-term Cell-phone Based Home Exercise on Biomarkers, Skeletal Muscle and Mortality in Patients With COPD Completed NCT01631019 Phase 2
39 A Randomized, Double-blind, Placebo-controlled, Parallel Group, 2-part Study Investigating the Effect of LIK066 on Body Weight in Dysglycemic (Prediabetes or Type 2 Diabetes) and Normoglycemic Patients With Elevated Body Mass Index Completed NCT02470403 Phase 2 LIK066;Placebo
40 A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction Among Patients With a History of Colorectal Adenomas and Elevated Body Mass Index Completed NCT01312467 Phase 2 metformin hydrochloride
41 A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Repeat Doses of Intranasal Oxytocin in Obese Adults Recruiting NCT03043053 Phase 2 oxytocin nasal spray;Placebo
42 Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse Recruiting NCT04758000 Phase 2 Metformin Hydrochloride
43 An Open Label, International, Multicenter, Dose Escalating Phase I/II Trial Investigating the Safety of Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma Active, not recruiting NCT01615029 Phase 1, Phase 2 Part 1 (Dose Escalation): Daratumumab;Part 2 (Dose Expansion): Daratumumab;Lenalidomide;Dexamethasone
44 Effects of Dietary Indole-3-Carbinol on Estrogen Metabolites Across a Wide Range of Body Mass Index: Implications for the Prevention of Endometrial Cancer in Obese Women Terminated NCT00988845 Phase 2
45 A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With End Stage Renal Disease and Healthy Subjects Completed NCT02135276 Phase 1 eravacycline
46 A High Resolution Pharmacokinetic/Pharmacodynamic Model of Propofol in Morbidly Obese Subjects Completed NCT01591148 Phase 1 propofol
47 Pilot Study of Resveratrol in Postmenopausal Women With High Body Mass Index Completed NCT01370889 Phase 1 resveratrol
48 Effect of Injection Site on the Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Doses of LY2605541 in Healthy Subjects, and Impact of Body Mass Index and Age on the Pharmacokinetics of LY2605541 Completed NCT01818245 Phase 1 LY2605541
49 To Evaluate the Pharmacokinetics and Safety of Yimitasvir Phosphate Capsules in Subjects With Moderate and Severe Liver Function Impairment and Healthy Subjects in a Single-center, Non-randomized, Open, Single-dose Administration Recruiting NCT04552808 Phase 1 Yimitasvir Phosphate;Yimitasvir Phosphate;Yimitasvir Phosphate;Yimitasvir Phosphate
50 The Healthy Lifestyles Passport Program: a Randomized Control Trial of a Prenatal Maternal Education Program to Prevent Infant and Childhood Obesity (HLPP) Unknown status NCT01649115

Search NIH Clinical Center for Body Mass Index Quantitative Trait Locus 1

Genetic Tests for Body Mass Index Quantitative Trait Locus 1

Anatomical Context for Body Mass Index Quantitative Trait Locus 1

MalaCards organs/tissues related to Body Mass Index Quantitative Trait Locus 1:

40
Breast, Heart, Liver, Bone, Kidney, Prostate, Ovary

Publications for Body Mass Index Quantitative Trait Locus 1

Articles related to Body Mass Index Quantitative Trait Locus 1:

(show top 50) (show all 30008)
# Title Authors PMID Year
1
Genetic studies of body mass index yield new insights for obesity biology. 61 57
25673413 2015
2
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. 61 57
20935630 2010
3
Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. 57 61
14569127 2003
4
A study of linkage and association of body mass index in the Old Order Amish. 57 61
12888987 2003
5
Genomewide linkage analysis of body mass index across 28 years of the Framingham Heart Study. 61 57
12355400 2002
6
Quantitative-trait loci influencing body-mass index reside on chromosomes 7 and 13: the National Heart, Lung, and Blood Institute Family Heart Study. 57 61
11713718 2002
7
Familial aggregation of body mass index and subcutaneous fat measures in the longitudinal Québec family study. 61 57
10096693 1999
8
A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. 57 61
9806549 1998
9
An autosomal genomic scan for loci linked to type II diabetes mellitus and body-mass index in Pima Indians. 61 57
9758619 1998
10
New genetic loci link adipose and insulin biology to body fat distribution. 57
25673412 2015
11
Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. 57
21706003 2011
12
The genetic contribution to non-syndromic human obesity. 57
19506576 2009
13
Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. 57
19151714 2009
14
Association of single-nucleotide polymorphisms in MTMR9 gene with obesity. 57
17855449 2007
15
Genetic pleiotropy between asthma and obesity in a community-based sample of twins. 57
16337451 2005
16
Genome-wide scan of obesity in the Old Order Amish. 57
11238509 2001
17
Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. 57
10523018 1999
18
Equivalent servings of free-range reindeer promote greater net protein balance compared to commercial beef. 61
33704030 2021
19
Influence of early-life body mass index and systolic blood pressure on left ventricle in adulthood - the Cardiovascular Risk in Young Finns Study. 61
33238748 2021
20
The effect of body mass index on the development of acute kidney injury and mortality in intensive care unit: is obesity paradox valid? 61
33745415 2021
21
Increased body mass index is associated with decreased imaging quality of point-of-care abdominal aortic ultrasonography. 61
32984964 2021
22
Association and potential mediators between socioeconomic status and childhood overweight/obesity. 61
33617865 2021
23
Long-term effects of participation in a prenatal exercise intervention on body weight, body mass index, and physical activity level: a 6-year follow-up study of a randomized controlled trial. 61
31327292 2021
24
Quantitative distribution of iodinated contrast media in body computed tomography: data from a large reference cohort. 61
32997173 2021
25
Association of Midlife Cardiovascular Risk Factors With the Risk of Heart Failure Subtypes Later in Life. 61
33238139 2021
26
Performance of Fitbit Charge 3 against polysomnography in measuring sleep in adolescent boys and girls. 61
33792456 2021
27
Evaluation of exercise capacity using two field tests in patients with metabolic syndrome. 61
31393177 2021
28
A Vegetarian Diet Is Associated with a Lower Risk of Cataract, Particularly Among Individuals with Overweight: A Prospective Study. 61
33309591 2021
29
Neovaginal Canal Dissection in Gender-Affirming Vaginoplasty. 61
33216669 2021
30
Rate of Force Development as a Predictor of Mobility in Community-dwelling Older Adults. 61
31917715 2021
31
Assessing Appetitive Traits Among Chinese Young Adults Using the Adult Eating Behavior Questionnaire: Factor Structure, Gender Invariance and Latent Mean Differences, and Associations With BMI. 61
31328547 2021
32
Population pharmacokinetics of gabapentin in patients with neuropathic pain: Lack of effect of diabetes or glycaemic control. 61
33118231 2021
33
Short-term changes and correlations of plasma spexin, kisspeptin, and galanin levels after laparoscopic sleeve gastrectomy. 61
33555434 2021
34
Investigating the Association Between Child Television Viewing and Measured Child Adiposity Outcomes in a Large Nationally Representative Sample of New Zealanders: A Cross-Sectional Study. 61
33811187 2021
35
Inverse association between bone mineral density and fibrinogen in menopausal women. 61
32602367 2021
36
Cardiovascular health behaviors and associations of sex, age, and education in adolescents - Results from the EVA Tyrol study. 61
33558093 2021
37
Effect of adenotonsillectomy in children with obstructive sleep apnea and major psychiatric disorders on obstructive apnea-hypopnea index and Epworth Sleepiness Scale scores. 61
33206042 2021
38
Improving the prognosis of renal patients: The effects of blood flow-restricted resistance training on redox balance and cardiac autonomic function. 61
33586254 2021
39
Chest Expansion and Lung Function for Healthy Subjects and Individuals With Pulmonary Disease. 61
33376188 2021
40
Nonintubated Versus Intubated Uniportal Thoracoscopic Segmentectomy for Lung Tumors. 61
32857994 2021
41
Relation of Body Mass Index to Adverse Right Ventricular Mechanics. 61
33385349 2021
42
Body mass index as an independent prognostic factor in glioblastoma. 61
33447892 2021
43
Modification of the effects of intensive systolic blood pressure control on kidney outcomes by baseline body mass index. 61
33538091 2021
44
Social media use as a predictor of higher body mass index in persons living with HIV. 61
32005080 2021
45
Pregestational body mass index, trimester-specific weight gain and total gestational weight gain: how do they influence perinatal outcomes? 61
31170838 2021
46
Body mass index and self-care behaviors related to oral health-related quality of life in patients with oral squamous cell carcinoma within three months posttreatment. 61
32910290 2021
47
Life-long body mass index trajectories and mortality in two generations. 61
33493649 2021
48
Malnutrition score and Body Mass Index as nutritional screening tools for hemodialysis patients. 61
33745613 2021
49
Effects of body mass index on outcomes of total knee arthroplasty. 61
33159565 2021
50
Beyond Asian-Specific Cutoffs: Gender Effects on the Predictability of Body Mass Index, Waist Circumference, and Waist Circumference to Height Ratio on Hemoglobin A1c. 61
32542494 2021

Variations for Body Mass Index Quantitative Trait Locus 1

Copy number variations for Body Mass Index Quantitative Trait Locus 1 from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 36096 1 71641212 72520993 Deletion NEGR1 body mass index

Expression for Body Mass Index Quantitative Trait Locus 1

Search GEO for disease gene expression data for Body Mass Index Quantitative Trait Locus 1.

Pathways for Body Mass Index Quantitative Trait Locus 1

GO Terms for Body Mass Index Quantitative Trait Locus 1

Sources for Body Mass Index Quantitative Trait Locus 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....